Educational reference only. Not medical advice. Research compounds are not for human or veterinary use.

KLOW benefits: what the four-peptide blend can and can't claim

KLOW is one of the most talked-about peptide blends: four peptides in one vial, marketed for healing, skin and inflammation. The pitch is that each ingredient covers a different part of repair. That idea is worth understanding, but so is the fact that the blend itself has never been studied. Here is what is in KLOW, what each part has been shown to do and what nobody knows yet.

What KLOW is

KLOW combines four peptides:

  • BPC-157, a 15-amino-acid fragment of a stomach protein studied for tendon, gut and soft-tissue healing in animals. See our BPC-157 brief.
  • TB-500, synthetic material based on thymosin beta-4, a protein that controls how cells move into a wound. See our TB-500 brief.
  • GHK-Cu, a copper-binding peptide found naturally in human blood and best known from skincare. See our GHK-Cu brief.
  • KPV, a three-amino-acid fragment of the hormone alpha-MSH studied for gut inflammation. See our KPV brief.

It is the Glow blend (BPC-157, TB-500 and GHK-Cu) with KPV added. Sellers use different ratios, so the amount of each component varies from product to product. See our KLOW brief.

The theory behind the blend

The rationale comes from animal and cell studies, where each peptide seems to act on a different step of healing:

  • BPC-157: new blood-vessel growth and protection of the gut lining.
  • TB-500: cell migration, by controlling the actin skeleton inside cells.
  • GHK-Cu: signals that tell skin cells to make collagen and other structural proteins.
  • KPV: calming inflammatory signaling inside cells, especially in the intestine.

Put together, the idea is "more pathways, more repair." That is a hypothesis. It has not been tested.

What the evidence shows for each part

BPC-157 and TB-500

Both have large bodies of animal work and almost no controlled human data. For BPC-157, a 2025 systematic review found 36 relevant studies, 35 of them in animals or cells. For TB-500, FDA reviewers noted in 2026 that no studies had been conducted on the fragment itself, although full-length thymosin beta-4 has been tested in human trials with mixed results. We cover both in detail in BPC-157 and TB-500 benefits: what the evidence shows.

GHK-Cu

GHK-Cu has the most human data of the four, but almost all of it is about creams applied to the skin:

  • In small cosmetic studies, GHK-Cu creams improved skin firmness, fine lines and skin density over about 12 weeks. In one study, a GHK-Cu cream increased collagen production in 70% of women treated, compared with 50% for vitamin C and 40% for retinoic acid (summarized in Pickart et al., 2015).
  • Many of these studies were small, some were presented only at conferences, and the main reviewer, Loren Pickart, discovered GHK-Cu and helped develop it commercially.
  • For injected GHK-Cu, we found no human trials. A 2018 review by Pickart and Margolina described only animal injection studies and said "the time has come for conducting actual clinical studies."

KPV

  • In mice with colitis, KPV taken by mouth reduced intestinal inflammation. It enters gut cells through a transporter called PepT1, which increases in inflamed tissue (Dalmasso et al., 2008).
  • KPV packed into nanoparticles targeted to the colon reduced colitis in mice at much lower amounts than free KPV (Laroui et al., 2010).
  • We found no published human trials of KPV.

What has never been studied

  • The blend itself. We found no published study of KLOW, of all four peptides together, or even of GHK-Cu combined with BPC-157.
  • Interactions. Nobody has tested whether the four peptides help, hinder or simply ignore each other when given together, or whether they stay stable mixed in one vial.
  • Safety of the combination. Each component has little human safety data on its own. Combining four multiplies the unknowns. FDA reviewers have raised theoretical concerns that BPC-157 and TB-500, which promote new blood-vessel growth and cell migration, could encourage tumor growth. That has not been shown in people, but long-term studies have not been done.

Quality: more ingredients, more room for error

A blend is harder to verify than a single peptide. A certificate of analysis has to confirm the identity and amount of four compounds, not one. In a 2026 analysis of about 6,300 test reports on research-grade peptides, one in ten TB-500 samples did not contain TB-500 at all. That study is a preprint and has not been peer reviewed, but it shows why lot testing matters. GHK-Cu also gives solutions a blue color; a change in color can mean the copper complex has broken down. Learn how to read a peptide COA.

Regulatory status

  • Not FDA-approved. KLOW is sold as a research compound, and none of its four components is an approved drug.
  • Compounding: in July 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, TB-500 and KPV for the list of substances pharmacies may compound. GHK-Cu was not part of that review; after its nominations were withdrawn in April 2026, it was slated for review by the committee by early 2027.
  • The October 2026 policy excludes blends. HHS's interim policy for 503A pharmacy compounding of six peptides, including BPC-157, TB-500 and KPV, requires each compounded product to contain a single active ingredient. A four-peptide blend like KLOW does not qualify, and the policy excludes products sold as research chemicals. Read what the July 2026 vote actually means.
  • Sport: BPC-157 and TB-500 are both banned by the World Anti-Doping Agency, so a blend containing them is banned too.

The bottom line

KLOW's appeal is the logic of covering four healing pathways at once. The evidence underneath is thin: animal studies for BPC-157, TB-500 and KPV, small skincare studies for GHK-Cu, and no studies at all of the four together. Any benefit of the blend, or any risk unique to it, is unknown.

Key references

This post is educational. It does not give dosing guidance or recommend using any compound in people or animals.

Educational content only

Peptide Knowledge is an educational reference. Nothing on this site is medical advice, a treatment recommendation or dosing guidance. Many compounds described here are not approved for human use and are sold for laboratory research only. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

All blog posts